Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02247193 · ClinicalTrials.gov registry record · Phase 1

Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair

A Phase 1 study of Cleft Palate and Scarring, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT02247193 is a Phase 1 study of Cleft Palate and Scarring that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 30 participants, below the 671-participant average among 9 other Cleft Palate trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02247193, a Phase 1 study of Cleft Palate and Scarring, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Objective: To determine if the use of botulinum toxin during primary cleft lip repair improves the cosmetic appearance of the cleft lip scar

Interventions

  • DRUG Botulinum Toxin Type A
  • DRUG Normal Saline Injection

Study Locations (1)

Texas

  • Memorial Hermann Hospital - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2015-12
Est. Completion 2020-01-13
Phase Phase 1

What the Registry Record Tells You About NCT02247193

The ClinicalTrials.gov registry entry for NCT02247193 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 671-participant average among 9 other Cleft Palate trials with a reported enrollment target (96% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cleft Palate appearing as the primary indexed condition, and to 2 interventions - of which Botulinum Toxin Type A is the first listed.

NCT02247193 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02247193 about?

NCT02247193 is a clinical study titled "Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair". Objective: To determine if the use of botulinum toxin during primary cleft lip repair improves the cosmetic appearance of the cleft lip scar

What is the current status of trial NCT02247193?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-12. Estimated completion is 2020-01-13.

What conditions does trial NCT02247193 study?

This clinical trial studies the following conditions: Cleft Palate, Scarring, Cleft Lip.

What interventions are being tested in trial NCT02247193?

The interventions under investigation include: Botulinum Toxin Type A (DRUG), Normal Saline Injection (DRUG).

Who is sponsoring clinical trial NCT02247193?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02247193 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cleft Palate

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.